Search

Background: Progressive ageing of the population has highlighted the importance of the relationship between physical function and frailty in patients with chronic disease. The aim of this study was to assess the association between exercise capacity and grip strength (GS) in a cohort of older patients involved in an exercise-based secondary prevention program., Methods: Sixty-five outpatients (aged 75±6 years) were included. Exercise capacity was assessed through the estimation of maximal oxygen consumption (V̇O2peak) and the measurement of walking speed (WS). GS was evaluated in the dominant arm using a hand-held dynamometer., Results: Patients with higher V̇O2peak and WS values exhibited significantly higher GS (P<0.01). GS was significantly related to WS (P<0.01) and V̇O2peak (P<0.01), and inversely associated with age (P<0.01). Results from linear multiple regression analysis (P<0.01) demonstrate that GS was strongly associated with WS (P<0.01) and age (P=0.01), while BMI, weekly LTPA, cardiovascular diagnosis, V̇O2peak and education were not., Conclusions: The evaluation of WS, V̇O2peak and GS was feasible and well tolerated. These preliminary results suggest that prescribing regular walking activity, educating subjects to perform it at higher average WS, can help to maintain physical function in older patients with cardiovascular disease.

Background: Exercise capacity has been inversely associated with the incidence and severity of hypertension and cardiovascular disease. Cardiopulmonary exercise testing (CPET) is the gold standard for the determination of exercise capacity (i.e. peak oxygen consumption [VO2peak]). However, CPET is not always readily available in clinical settings. A moderate 1-km treadmill walking test (1k-TWT) has been demonstrated to be a valid and simple tool for the assessment of exercise capacity in outpatients with cardiovascular disease. The aim of this study was to examine the association between VO2peak estimated during a 1k-TWT and all-cause mortality in patients with hypertension and stable coronary artery disease., Methods: A total of 597 patients aged 63 ± 9 years underwent the 1k-TWT, and were followed up for all-cause mortality. The 1k-TWT was individualized at a moderate perceptually-regulated exercise intensity (11-13 on the 6-20 Borg scale). Age, body mass index, heart rate, and time to complete the 1k-TWT were entered into the equations originally validated for VO2peak estimation. Subjects were stratified into quartiles according to baseline VO2peak, and mortality risks were calculated., Results: During a median follow-up of 7.7 years, 79 deaths from any cause occurred, and resulted 36, 28, 10 and 5 for the first, second, third, and fourth quartile respectively. Compared to the lowest quartile (average VO2peak 18.1 ml/kg/min, n=149), the full-adjusted hazard ratios were 0.80 (p=0.49), 0.31 (p=0.02), and 0.13 (p=0.005) for the second (average VO2peak 21.8 ml/kg/min, n=150), third (average VO2peak 24.4 ml/kg/min, n=149), and fourth quartile (average VO2peak 28.7 ml/kg/min, n=149), respectively., Conclusions: VO2peak estimated by the 1k-TWT is a strong and independent predictor of all-cause mortality in patients with hypertension and coronary artery disease. Assessing VO2peak by the 1k-TWT can be a useful, simple and low-cost tool to stratify and follow up hypertensive patients with cardiovascular disease through cardiac rehabilitation and secondary prevention programs.

Background: Maximal cardiopulmonary exercise testing (CPX) is the gold-standard for cardiorespiratory fitness assessment in chronic heart failure (CHF) patients. However, high costs, required medical supervision, and safety concerns make maximal exercise testing impractical for evaluating mobility-impaired adults. Thus, several submaximal walking protocols have been developed and currently used to estimate peak oxygen consumption (VO 2 peak) in CHF patients. However, these tests have to be performed at close to maximum exercise intensity. The aim of this study was to examine the validity of a 500-m treadmill-walking test carried out at moderate intensity for estimating VO 2 peak in community-dwelling adult and elderly patients with CHF and reduced left ventricular ejection fraction (HFrEF)., Methods: Forty-three clinically stable men with HFrEF (age 67.7 ± 9.2 years, and left ventricular ejection fraction, LVEF 38% ± 6%) underwent exercise testing during an outpatient cardiac rehabilitation/secondary prevention program. Each patients completed a CPX, and a moderate and self-paced (11-13/20 on the Borg scale) 500-m treadmill-walking test. Age, weight, height, walk time, and heart rate during the 500-m test were entered into prediction equations previously validated for VO 2 peak estimation from a 1000-m walking test in patients with cardiovascular disease and preserved LVEF., Results: Directly measured and estimated VO 2 peak values were not different (21.6 ± 4.9 vs 21.7 ± 4.6 mL/kg/min). The comparison between measured and estimated VO 2 peak values yielded a correlation of R = 0.97 (SEE = 0.7 mL/kg/min, P < 0.0001). The slope and the intercept coincided with the line of identity (Passing and Bablock analysis, P = 0.50). Residuals were normally distributed, and the examination of the Bland-Altman analysis do not show systematic or proportional error., Conclusions: A moderate and self-regulated 500-m treadmill-walking test is a valid tool for VO 2 peak estimation in patients with HFrEF. These findings may have practical implications in the context of transitioning from clinically based programs to fitness facilities or self-guided exercise programs in adults and elderly men with HFrEF.

Objective: To determine the relationship between walking speed (WS) maintained during a 1 km test and its improvement on hospitalisation in cardiac outpatients who were referred to an exercise-based secondary prevention programme., Methods: Hospitalisation was assessed in 1791 patients 3 years after enrolment and related to the WS achieved during a 1 km walk at moderate intensity on a treadmill. Hospitalisation was also assessed during the fourth-to-sixth years as function of improvement in WS in 1111 participants who were re-evaluated 3 years after baseline., Results: Three-year hospitalisation rate across tertiles of baseline WS was 50% for the slow walkers (2.7±0.6 km/hour), 41% for the moderate (4.1±0.3 km/hour) and 25% for the fast walkers (5.2±0.5 km/hour) (p for trend <0.0001), with adjusted HRs (95% CI) of 0.93 (0.74 to 1.17, p=0.53) for intermediate and 0.58 (0.43 to 0.78, p=0.0003) for fast. Every 1 km/hour increase in WS was associated with a 21% reduction in hospitalisation (p<0.0001). Hospitalisation from the fourth-to-sixth years was lower across tertiles of improved WS, with 44% for the low (0.2±0.4 km/hour), 34% for the intermediate (0.8±0.2 km/hour) and 30% for the high tertile (1.6±0.4 km/hour) (p for trend <0.0001). Adjusted HRs were 0.68 (p=0.002) for the intermediate and 0.58 (p<0.0001) for the high tertile. Every 1 km/hour increase in WS was associated with a 35% reduction in hospitalisation (p<0.0001)., Conclusion: Improvement in WS is associated with a significant, dose-dependent lower rate of all-cause hospitalisation in cardiac outpatients. WS is a simple, easily applied and clinically useful tool for cardiac patients undergoing secondary prevention., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)

Purpose: To determine whether a moderate 1-km treadmill walking test (1KTWT) could be used to predict peak oxygen uptake VO(2)peak) in patients with cardiovascular disease., Methods: One hundred seventy-eight male patients, aged 38 to 83 years, completed a VO(2)peak treadmill test and a 1KTWT using a self-regulated intensity of 11 to 13 of 20 on the Borg scale. Multivariable regression analysis was used to develop equations for predicting VO(2)peak in a development group (n = 110), both for subjects prescribed and not prescribed a β-blocking agent (BB/NBB, 66/44). These equations were then applied to a cross-validation and reproducibility group (n = 68, BB/NBB, 37/31), who completed the protocol twice within 2 weeks., Results: Analysis from 1KTWT in the development group showed that age, body mass index, walking speed, and heart rate were the most potent predictors of VO(2)peak. Measured and predicted VO(2)peak were not significantly different, and were strongly associated among both the NBB (r = 0.81, P < .0001) and BB (r = 0.69, P < .0001) groups, with a mean residual of approximately 1.0 mL·kg(-1)·min(-1). When applied to the cross-validation and reproducibility group, the equations similarly yielded strong associations (r = 0.64, P < 0.001 and r = 0.71, P < 0.001 for the NBB and BB groups, respectively), with no significantly differences between measured and predicted VO(2)peak. Mean test-retest differences for measured and predicted VO(2)peak were between 0.1 and -0.5 mL·kg(-1)·min(-1)., Conclusions: Equations developed from the 1KTWT accurately predicted VO(2)peak in patients with cardiovascular disease. The model may represent a valid, low cost, and simple tool for indirect estimations of cardiorespiratory fitness in an outpatient setting.